These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year
August 27, 2016 at 09:12 AM EDT
PCSK-9 inhibitors lowered LDL-C by roughly 60% in clinical trials, but do their costs far outweigh their benefits?
